Bayer's Debt Forecast Shrinks as Crop Science Powers a Beat That Has Analysts Reaching for New Targets
Published on 08/06/2026 at 18:41 | Redaktion boerse-global.de
The market's attention may be fixed on a Missouri courtroom in September, but it was Tuesday's second-quarter scorecard that gave Bayer shareholders their most tangible reason for optimism in months. The Leverkusen-based group beat consensus expectations with adjusted earnings per share of EUR 0.95 against the EUR 0.77 analysts had penciled in, and the response from the sell-side was swift — several prominent houses lifted their price targets within 24 hours.
Agribusiness Carries the Quarter
Group revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to EUR 10.872 billion, while EBITDA before special items improved 1.9 percent to EUR 2.144 billion. Net income swung to a positive EUR 219 million, reversing a loss in the year-earlier period.
The engine room was unmistakably Crop Science. The agriculture division lifted its quarterly EBITDA by 30.2 percent to EUR 902 million, helped by efficiency programs and robust US demand for Dicamba seed. That performance more than offset a 3.6 percent EBITDA decline in the pharmaceuticals unit, which slipped to EUR 1.055 billion as the blockbuster blood thinner Xarelto lost ground. Within the pharma portfolio, the newer products told a brighter story: cancer drug Nubeqa generated EUR 820 million in quarterly sales, with Nubeqa and kidney-disease treatment Kerendia growing 64 percent and 83 percent respectively.
A Leaner Debt Profile Emerges
Perhaps the most striking revision came on the balance sheet. Bayer now guides to net financial debt of EUR 29 to 30 billion by the end of 2026 — a meaningful step down from the EUR 32 to 33 billion range previously communicated. As of June 30, debt stood at EUR 33.647 billion. Management attributes the expected improvement primarily to an equity investment from Apollo anticipated in the second half of the year.
That deleveraging trajectory, alongside the operational beat, proved persuasive for analysts. Goldman Sachs' James Quigley raised his price target from EUR 62.50 to EUR 63.50 on Wednesday, keeping a "Buy" rating and citing both the improving financials and progress on the group's legal risk assessment. UBS went further, lifting its target from EUR 52 to EUR 62 with a "Buy" stance, noting that operating results had topped consensus estimates by 10 percent. The DZ Bank and JPMorgan also joined the upgrade wave, with the former raising its fair value from EUR 54 to EUR 60.
Legal Calendar Shifts, but the Wind Blows Favorably
On the litigation front, the timeline has slipped. Bayer and plaintiffs' attorneys jointly requested that the final court hearing on the USD 7.25 billion glyphosate class-action settlement in Missouri be moved from August 19 to September 10. The delay stems from opt-out requests filed by individual claimants that must be processed first.
As Bayer's management emphasizes progress on its legal risk assessment, the same principle applies closer to home: UK employers face their own compliance duties under health and safety law, and failing to document workplace risks properly can prove costly. A free toolkit with 41 ready-to-use templates and checklists helps you identify hazards and keep legally sound records — covering fire safety, manual handling, first aid and lone working. Download the free Risk Assessment Toolkit
The legal backdrop, however, has brightened considerably. A late-June ruling by the US Supreme Court in the "Durnell" case — decided 7 to 2 in favor of Bayer subsidiary Monsanto — has strengthened the company's negotiating position, according to CEO Bill Anderson. Management also moved to reorganize the US glyphosate business into a standalone unit called "Ruveon," a step that adds operational flexibility in a politically sensitive area. Anderson kept the door open on a potential full breakup of the group into agriculture, pharma and consumer health units, though he stopped short of suggesting such a move is imminent, emphasizing that operational performance and debt reduction remain the immediate priorities.
Shares Climb, but Headroom Remains
The market's mood has shifted visibly. The stock closed Wednesday at EUR 49.40, up 2.28 percent on the day, and has gained 33.48 percent since the start of the year. Over the past seven trading sessions, the shares have advanced 2.02 percent. Still, the title sits roughly 8.3 percent below its 52-week high of EUR 53.86, reached in early July.
Investors now have two clear dates on the calendar: the September 10 hearing in Missouri, where the court will decide on the glyphosate settlement, and the third-quarter results due November 3. In the meantime, Bayer continues to push its digital agriculture agenda — the AI-driven pest-detection platform "MagicTrap 2" for oilseed rape was rolled out to 14 additional European markets in July, including the UK.
